Biomarker: ER

Histology type: endometrial carcinoma

Stage: risk

Study type: Retrospective multicenter study

Followed up time :

Subgroup 1 name : negative

Subgroup 1 number: 151

Subgroup 2 name: positive

Subgroup 2 number: 612

Conclusion: p53/L1CAM/ER/PR expression could serve as indicator for surgical staging and refine selective adjuvant treatment by incorporation into the ESMO-ESGO-ESTRO risk classification.

Sample type : tissue

Sample method: immunohistochemistry

Expression pattern : p53/L1CAM/ER/PR expression,for ER/PR-

Expression elevation: For ER and PR, the number of stained tumor nuclei was scored. Cases were also dichotomized, using 10% as a cut-off value.ER and/or PR expression was considered abnormal when <10% nuclear staining was present (ER/PR-).

Statictics: Mean (SD)

Cohort age: 65.2 ± 10.2

Funtion Uniprot: Binds to an ERR-alpha response element (ERRE) containing a single consensus half-site, 5'-TNAAGGTCA-3'. Can bind to the medium-chain acyl coenzyme A dehydrogenase (MCAD) response element NRRE-1 and may act as an important regulator of MCAD promoter. Binds to the C1 region of the lactoferrin gene promoter. Requires dimerization and the coactivator, PGC-1A, for full activity. The ERRalpha/PGC1alpha complex is a regulator of energy metabolism. Induces the expression of PERM1 in the skeletal muscle.

UniProt ID: P11474

UniProt Link: https://www.uniprot.org/uniprotkb/P11474/entry

Biological function from UniProt: #Transcription #Transcription regulation

Molecular function from UniProt:

Subcellular UniProt: #Cytoplasm #Nucleus

Alternative name from UniProt:

Recommended name: Steroid hormone receptor ERR1

Gene name from HGNC: ESRRA (ERR1, ERRa, ERRalpha, ESRL1, NR3B1)

HPA class: Nuclear receptors Transcription factors

AlphaFold DB: P11474

AlphaFold Link: https://alphafold.ebi.ac.uk/entry/P11474

Induction: Induced by PGC1alpha in a number of specific cell types including heart, kidney and muscle.

HPA link: https://www.proteinatlas.org/ENSG00000173153-ESRRA

Tissue specificity RNA from HPA: Tissue enhanced (skeletal muscle)

Tissue expression from HPA: General cytoplasmic expression.

Single cell type specificity Cell type enhanced (Hepatocytes, Proximal enterocytes, Distal enterocytes)

Immune cell specificity: Low immune cell specificity

Subcellular summary HPA Located in Nucleoplasm, Nucleoli fibrillar center, Microtubules, Cytokinetic bridge (Single cell variability, CCD Protein)

Cancer prognostic summary HPA Prognostic marker in renal cancer (favorable)

Pathology link: https://www.proteinatlas.org/ENSG00000173153-ESRRA/pathology

Pathology endo: https://www.proteinatlas.org/ENSG00000173153-ESRRA/pathology/endometrial+cancer

Survival figure legend: RFS for ESMO-ESGO-ESTRO risk groups and p53-expression. B. RFS for ESMO-ESGO-ESTRO risk groups and L1CAM-expression C. RFS for ESMO-ESGO-ESTRO risk groups and ER/PR-expression.

Survival curve link: https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/9bdaf4c2-b783-4a6d-8cae-7682434613a8/gr3.jpg

OMIM: 601998

OMIM link2: https://www.omim.org/entry/601998

HGNC ID: HGNC:3471

HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:3471